A 52-year-old Japanese woman being treated for type 1 diabetes showed forgetfulness and microcytic anemia with a high serum ferritin concentration. Serum and brain radiological examinations revealed aceruloplasminemia, which was confirmed by genetic testing. Aceruloplasminemia is characterized by the triad of retinal degeneration, diabetes mellitus, and adult-onset disorder of the extrapyramidal system. Though physicians should treat such patients earlier, it is difficult to diagnose the disease before the presentation of neurological symptoms. Despite the presence of microcytic anemia, aceruloplasminemia patients usually have a high serum ferritin concentration due to the complete absence of ceruloplasmin ferroxidase activity. Thus, physicians should consider aceruloplasminemia when diabetic patients present with microcytic anemia and a high serum ferritin concentration.
Introduction
Aceruloplasminemia is a rare disease in which a ceruloplasmin (CP) gene mutation results in a defect or dysfunction of CP (1, 2) . CP transports iron from the cell cytoplasm to capillaries, whereupon iron binds to ferritin and joins the blood stream (3) . As CP is the only protein responsible for transporting iron within cells, iron accumulates in cells without adequate CP function and the serum ferritin concentration increases.
Iron accumulates especially in the eye, brain, pancreas, and liver in aceruloplasminemia patients (1, 2) . Thus the characteristic triad of aceluroplasminemia is retinal degeneration, diabetes mellitus, and adult-onset disorder of the extrapyramidal system. But the phenotype of this disease is usually heterogeneous (4) (5) (6) (7) and early diagnosis is difficult using the triad. Here we report the possibility of using a high serum ferrtin concentration accompanied by microcytic anemia for early diagnosis of aceluroplasminemia.
Case Report
A 52-year-old Japanese woman was admitted to our hospital because of her poor glycemic control. She was diagnosed with type 1 diabetes mellitus at age 19 and began insulin injection. She had been healthy until the age of seventeen years old, then she felt thirsty and general fatigue at age 18 and hyperglycemia was revealed for the first time. She had no family history of diabetes. She did not take any medication and her diabetes progressed slowly. Her body mass index was about 18 kg/m 2 when she was diagnosed with type 1 diabetes. At this time, she was also revealed to have microcytic anemia, which subsequently did not respond to iron supplements. Her glycemic control was very poor and she had syncope and convulsions caused by hypoglycemia about once a month. At the age of approximately 49, she was observed to be forgetful. Her speech was almost normal and there was no Kayser-Fleischer ring or involuntary movement. There was no atrophy of the limb muscles, and her muscle power was normal. Deep tendon reflexes were not detected but, except for vibratory sense of the feet, sensation was normal. Her capacity to secrete insulin was exhausted. She had not been previously examined for antiglutamic acid decarboxylase (GAD) or anti-tyrosine phosphatase IA-2 antibodies. Her GAD antibody was negative on this admission. Her diabetes was tolerably controlled by continuous subcutaneous insulin infusion therapy.
Although her forgetfulness might have been the result of frequent hypoglycemia, we conducted computed tomography (CT) and magnetic resonance imaging (MRI) of her brain to rule out intracranial disease. We also reconfirmed that she did indeed have microcytic anemia.
Her brain CT showed hyper-intensities in the basal ganglia ( Fig. 1 ) and thalamus. The basal ganglia and thalamus exhibited hypo-intensities on both the T1-and T2-weighted MRIs (Fig. 2) . Her liver showed diffuse hyper-intensity and her pancreas showed a slightly lower intensity than the liver on the CT scans. Her laboratory data revealed that serum CP and copper concentrations were undetectable (Table 1) .
Serum iron concentration was very low and ferritin concentration was very high. Given these findings, we diagnosed her with aceruloplasminemia.
According to her family pedigree (Fig. 3) , her parents were first cousins. Her older sister was 56 years old at the time of her admission and had been revealed to have microcytic anemia at age 43. At age 53, this sister began treatment for type 2 diabetes mellitus; she is being treated with gliclazide and metformin and maintains good glycemic control. She did not show any neurological symptoms. Her CT scan showed a diffuse high-intensity area in the liver. The sister's laboratory data also revealed undetectable levels of copper and ceruloplasmin; ferritin concentration was 461 ng/ mL despite microcytic anemia, and iron concentration was 27 μg/dL as shown in Table 1 . Thus, the sister also suffered from aceruloplasminemia. Neither of them was diagnosed with retinal pigmentation.
After obtaining informed consent, molecular analyses of the CP gene in this family were performed at the Shinshu University School of Medicine as previously described (6) . PstI restriction fragment length polymorphisms revealed that the patient and her sister were homozygous for the 319 delT point mutation, and that her parents were heterozygous for this mutation (Fig. 4) . This point mutation made a stop codon on the ceruloplasmin gene, then caused ceruloplasmin protein deficit.
Discussion
Aceruloplasminemia patients develop retinal pigment degeneration, diabetes mellitus, and extrapyramidal system dysfunction after middle age. Although the type of diabetes mellitus is usually type 2, retinal pigment degeneration may be difficult for physicians to notice. In the present case, the clue to diagnosing aceruloplasminemia was provided by the radiological examinations undertaken to determine underlying causes of forgetfulness. It is important to bear in mind that this patient had microcytic hypochromic anemia for a long time. While the patient's older sister suffered from type 2 diabetes beginning in her 40's, and has no neurological symptoms to date, she does have hypochromic anemia now. Therefore, as neurological damage does not recover easily, we suggest that checking serum copper and ceruloplasmin in patients that present with microcytic hypochromic anemia with high serum ferritin concentration may aid in the early diagnosis of aceruloplasminemia, especially in patients with diabetes. Detecting a high ferritin concentration in patients with microcytic anemia may motivate physicians to further investigate copper metabolism.
Hatanaka et al also emphasized that aceruloplasminemia should be kept in mind as a differential diagnosis in patients with juvenile-onset diabetes (6) . They reported the case of a patient who was diagnosed with aceruloplasminemia subsequent to type 1 diabetes. This case also revealed microcytic hypochromic anemia and a high serum ferritin concentration. We suspect that the diabetes in the present patient is secondary to the aceruloplasminemia, as she has not been checked for the immunological marker of type 1 diabetes. While a differential diagnosis of sideroblastic anemia, thalassemia or spherocytosis may be necessary in such cases, these all show hemolysis tendencies or inappropriate hematogenesis. Chronic inflammation may also be ruled out based on many other findings.
The initial therapy for aceruloplasminemia is to chelate iron (8, 9) . Both our patient and her sister were started on defferoxamine. However, iron should also be removed from inside the cell, which is now very difficult. Thus, it is not clear whether chelation therapy is effective in stopping or delaying progression of the disease, and unfortunately, not certain that the patient will benefit from the early diagnosis now.
Experimentally, accumulation of iron in the cytoplasm causes oxidative stress (10) . Recently, it was reported that oxidative stress plays one of the pivotal roles in central nervous system damage in aceruloplasminemia (11) . If oxidative stress is one of the major causes of cell damage in aceruloplasminemia, another way to treat it may be to reduce oxidative stress using a drug such as deferiprone (12) . To evaluate the efficacy of anti-oxidative drugs, early diagnosis is required.
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